HC Wainwright Cuts Earnings Estimates for Alpha Tau Medical

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – Research analysts at HC Wainwright decreased their FY2025 EPS estimates for shares of Alpha Tau Medical in a research note issued on Wednesday, August 13th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.48) per share for the year, down from their previous estimate of ($0.47). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Alpha Tau Medical’s FY2026 earnings at ($0.47) EPS.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

Alpha Tau Medical Stock Performance

Shares of DRTS stock opened at $3.28 on Friday. The firm’s 50 day moving average price is $3.10 and its 200-day moving average price is $2.91. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.81 and a current ratio of 10.52. Alpha Tau Medical has a one year low of $2.11 and a one year high of $4.39. The firm has a market cap of $278.21 million, a P/E ratio of -6.83 and a beta of 0.99.

Hedge Funds Weigh In On Alpha Tau Medical

Several large investors have recently made changes to their positions in DRTS. XTX Topco Ltd acquired a new position in shares of Alpha Tau Medical in the first quarter worth $53,000. Renaissance Technologies LLC increased its position in shares of Alpha Tau Medical by 188.7% during the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock worth $127,000 after acquiring an additional 26,800 shares during the period. Northern Trust Corp increased its position in shares of Alpha Tau Medical by 112.6% during the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock worth $151,000 after acquiring an additional 25,770 shares during the period. Finally, Kovitz Investment Group Partners LLC increased its position in shares of Alpha Tau Medical by 601.4% during the first quarter. Kovitz Investment Group Partners LLC now owns 226,320 shares of the company’s stock worth $568,000 after acquiring an additional 194,055 shares during the period. 2.65% of the stock is currently owned by institutional investors and hedge funds.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.